Interview with Joe Moore, Founder & CEO of Psychedelics Today

Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
Clinical Trial Progress
Molecules & Compounds Pipeline
The Company’s war chest to sustain growth as a biotech company in a new industry

But why invest in psychedelic stocks?
Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.

So our top 5 Shroom Stock Pics for 2021 are:
5. Cybin ( CYBN on NEO & CLXPF on the OTC)
4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
3. Compass Pathways (CMPS on Nasdaq)
2. Atai Life Sciences – Soon to IPO on the Nasdaq
1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Numinus (NUMI) : https://numinus.ca/
Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/

Timestamps:
0:00 – Intro
1:58 – Ranking criteria
3:42 – Cybin (CYBN) ( CLXPF)
6:24 – Numinus Wellness ( NUMI)
10:04 – Compass Pathways (CMPS)
13:52 – Atai Life Sciences
18:50 – MindMed ( MMED / MNMD/ MMQ )

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPSStock

Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!

P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”

Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.

Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.

Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?

🎵 Music: www.bensound.com

Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Cybin #Psilocybin #Psychedelics